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Objectives: Over the last decade, there has been a signif-
icant increase in primary endoluminal therapy for critical limb
ischemia (CLI; rest pain and tissue loss) of the lower extremity
(LE) with limited reporting on patient centered outcomes
using the new objective performance goals of the SVS.
Methods: A prospective database of patients undergo-
ing endovascular treatment of the LE for CLI between
2000 and 2011 was queried. Patient centered outcomes of
clinical efficacy (CE; absence of recurrent symptoms, main-
tenance of ambulation and absence of major amputation),
amputation-free survival (AFS; survival without major am-
putation) and freedom from major adverse limb events
(MALE; Above ankle amputation of the index limb or
major re-intervention (new bypass graft, jump/interposi-
tion graft revision) were evaluated.
Results: 728 patients (60% male, age 6814years)
underwent LE interventions for CLI (66% tissue loss). 39%
had both SFA and tibial interventions. 71% had diabetes
mellitus, 64% had hyperlipidemia and 37% had chronic
renal insufficiency. Technical success was 96%. Overall
MACE was 3% and MALE was 22% at 30 days. At 5 years,
CE was 425%, (MeanSEM), AFS 417% and MALE
514%. CE was significantly different in those presenting
with rest pain and tissue loss (Fig).
Conclusions: Endoluminal therapy for CLI is associ-
ated with an early lowMACE but a high MALE. Longer-
term outcomes remain relatively poor with less that a
40% success in patient centered outcomes at 5 years.
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Objectives:Clinical trials currently evaluating stem cell
therapy for patients with critical limb ischemia are con-
ducted with different protocols, including use of different
stem cell populations and different injection protocols,
providing little means to compare trials and guide therapy.
Accordingly, we developed a murine model of severe isch-
emia to allow methodical testing of relevant clinical
parameters.
Methods: High femoral artery ligation and total exci-
sion of the superficial femoral artery was performed on
C57BL/6 mice. MNC were isolated from the bone mar-
row of donor mice and injected into the semimembranosus
or gastrocnemius muscle. Vascular and functional out-
comes were measured using invasive Doppler, laser Dopp-
ler perfusion imaging, and the Tarlov and ischemia scores.
Histological analysis included quantification of muscle fiber
area and number as well as capillary density.
Results: Blood flow and functional outcomes were
improved in MNC-treated mice as compared to controls
over a 4-week time course (Flow: P  .0001; Tarlov: P 
.0004; ischemia score: P .0002). MNC-treated mice also
showed greater gastrocnemius fiber area (P  .0053) and
increased capillary density (P  .0004). Dose-response
analysis showed increased angiogenesis and gastrocnemius
fiber area but no changes in macroscopic vascular flow or
functional scores. Mice injected proximally to the ischemic
area had overall similar functional outcomes to mice in-Fig.
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jected more distally, but increased muscle flow, capillary
density, and gastrocnemius fiber area (P  .05).
Conclusions: Our severe ischemia model is reliable
and shows a response to MNC-treatment for both func-
tional and vascular outcomes. A dose response to MNC
injection appears to be present suggesting that an optimal
cell number for stem cell therapy exists and that preclinical
testing needs to be performed to optimally guide human
trials. Injection of MNC proximal to the site of ischemia
may provide some different outcomes and warrants addi-
tional study.
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Objectives: Branched and fenestrated repair is an effec-
tive method for treatment of complex aortic aneurysms.
However, the long-term durability of branches is not well
reported.
Methods: Prospective data collected for all patients
enrolled in a physician sponsored investigational device
exemption trial for branched and fenestrated endografts
was analyzed. Imaging studies and electronic records were
used to supplement the prospectively collected dataset
when necessary. Incidence of branch stent reintervention,
endoleak repair, stent fracture, migration, rupture and
death were calculated. Time to event analysis was per-
formed for a composite endpoint of reintervention for any
branch. Univariable and multivariable analysis were per-
formed to identify related variables. Device failure was
reported as a function of exponential decay to capture the
loss of freedom from complications over time.
Results: Between the years 2001 and 2010, 650 pa-
tients underwent endovascular aortic repair with branched
or fenestrated devices. Through 9 years of follow up (mean
3 years [SD 2.3]), secondary procedures were performed
for 0.6% of celiac, 4% of SMA, 6% of right renal, and 5% of
left renal artery stents.Mean time to reintervention was 237
days (SD 354 days). The 30 day, 1 year and 5 year freedom
from any branch intervention was 98% (95% confidence
interval [CI] 96 - 99%), 94% (95% CI 92 - 96%), 84% (95%
CI 78 - 90%) respectively (Fig). Death resulted from branch
stent complications in only 2 patients, related to SMA
thrombosis. Multivariable analysis revealed no factors as
independent predictors of branch reintervention.
Conclusions: Branches, following branched or fenes-
trated aortic repair, appear to be durable, and are rarely the
cause of patient death. The absence of long-term data on
the branch patency in open repair precludes comparison,
yet the lower morbidity and mortality risk coupled with
longer-term durability data will further alter the balance of
repair options.
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Objectives: To present our results with an algorithmic
approach to complex “hybrid” open/endovascular aortic
arch repair, based upon the extent of aortic disease and
patient comorbidities.
Methods: Between August 2005 and December 2011,
80 patients underwent hybrid arch repair by three principal
procedures: zone 0 endograft coverage with aortic arch
debranching (zone 0, n45), zone 1 endograft coverage
with extra-anatomic left carotid revascularization (zone 1,
n19), and stage II endovascular completion following
stage I total arch repair (stented elephant trunk, n16).
Results:Median patient age was 69 years [interquartile
range (IQR): 56, 74]. Sternotomy, cardiopulmonary by-
pass, and circulatory arrest were required in 45 (56%), 18
(23%), and 7 (9%) patients, respectively, to allow for arch
debranching or concomitant aortic or cardiac procedures,
including ascending/- hemi-arch replacement in 8 (18%)
patients undergoing zone 0 repair. All 16 (100%) stented
elephant trunk procedures and 9 (20%) zone 0 procedures
were staged, with the endovascular component performed
a median of 72 days [IQR: 11, 155 days] following the
open arch component. In-hospital rates of death, stroke,
and permanent paraplegia/paresis were 9% (n7), 4%
(n3), and 1% (n1), respectively. At a mean follow-up of
27 /- 21 months, 11 (14%) patients required secondary
re-intervention for type 1 (n4), type 2 (n5), or type 3
(n1) endoleak, or arch vessel bypass graft revision (n1).
Three (4%) patients experienced acute retrograde type A
dissection following stent graft placement and 3 (4%) re-
quired late reintervention for new aortic disease. Kaplan-
Meier estimates of survival at 1, 3, and 5 years were 73%,
63%, and 54%, respectively.
Conclusions: Hybrid aortic arch repair can be tailored
to patient anatomy and comorbid status to allow complete
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